Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized controlled study of omeprazole, esomeprazole, and omeprazole + itopride for GERD
ChiCTR-IPR-17011872Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of omeprazole, esomeprazole and itopride in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: GERD-Q, Extraesophageal symptom assessment and 5 more. Started Jul 2017; status: recruiting.
02
Drugs
omeprazoleesomeprazoleitopride
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ChiCTR-IPR-17011872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011872.